Psilocybin in pharmacotherapy of obsessive-compulsive disorder
Pharmacological Reports · 2024
DOI: 10.1007/s43440-024-00633-1 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmacological Reports, 2024. Verfasst von Maja Owe-Larsson und 4 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Center for Preclinical Research, Department of Experimental and Clinical Physiology, Medical University of Warsaw, Banacha 1B, Warszawa…. Hauptthemen laut MEDLINE: Obsessive-Compulsive Disorder, Psilocybin, Hallucinogens. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 147 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Obsessive-compulsive disorder (OCD) is a chronic mental disease that affects approximately 2% of the population. Obsessions and compulsions are troublesome for patients and may disturb their everyday activities. The pathogenesis of this disease is still not fully elucidated, but dysfunctions of serotonin-, dopamine- and glutamate-mediated neurotransmission together with early maladaptive schemas seem of importance. Pharmacological treatment includes drugs affecting the serotoninergic, dopaminergic, and glutamatergic systems, such as selective serotonin reuptake inhibitors (SSRIs). Providing that up to 40% of patients with OCD are resistant to the currently available medications, there is a need for novel and effective therapies. Recent discoveries suggest that psilocybin, a non-physically addictive psychoactive substance, may ameliorate disease symptoms. When used in appropriate doses and under strict clinical control, psilocybin appears as a valuable treatment for OCD. This narrative article provides a thorough overview of OCD’s etiology, current treatment options, and the emerging evidence supporting psilocybin’s efficacy in managing OCD symptoms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Center for Preclinical Research, Department of Experimental and Clinical Physiology, Medical University of Warsaw, Banacha 1B, Warszawa, 02-097, Poland. maja.owelarsson@gmail.com.
- Laboratory of Center for Preclinical Research, Department of Experimental and Clinical Physiology, Medical University of Warsaw, Banacha 1B, Warszawa, 02-097, Poland. katarzyna.kaminska@wum.edu.pl.
- Laboratory of Center for Preclinical Research, Department of Experimental and Clinical Physiology, Medical University of Warsaw, Banacha 1B, Warszawa, 02-097, Poland.
- Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warszawa, Poland.
Zitieren
APA
Owe-Larsson, M., Kamińska, K., Buchalska, B., Mirowska-Guzel, D., & Cudnoch-Jędrzejewska, A. (2024). Psilocybin in pharmacotherapy of obsessive-compulsive disorder. Pharmacological Reports. https://doi.org/10.1007/s43440-024-00633-1
Vancouver
Owe-Larsson M, Kamińska K, Buchalska B, Mirowska-Guzel D, Cudnoch-Jędrzejewska A. Psilocybin in pharmacotherapy of obsessive-compulsive disorder. Pharmacological Reports. 2024. doi:10.1007/s43440-024-00633-1
BibTeX
@article{OweLarsson2024,
author = {Owe-Larsson, Maja and Kamińska, Katarzyna and Buchalska, Barbara and Mirowska-Guzel, Dagmara and Cudnoch-Jędrzejewska, Agnieszka},
title = {Psilocybin in pharmacotherapy of obsessive-compulsive disorder},
journal = {Pharmacological Reports},
year = {2024},
doi = {10.1007/s43440-024-00633-1}
}
EUVIMED